APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Gene Therapy Medicine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gene Therapy Medicine Market Outlook and Growth Opportunities 2026

Report ID 173994620430 December 2025192 pages

Choose your research edition.

Industry ResearchGene Therapy Medicine Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Gene Therapy Medicine Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Gene Therapy Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gene Therapy Medicine Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Gene Therapy Medicine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Gene Therapy Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gene Therapy Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gene Therapy Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gene Therapy Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gene Therapy Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gene Therapy Medicine market include Vical Inc., Spark Therapeutics, Sangamo, Dimension Therapeutics, Celladon, Bluebird Bio, Avalanche Bio and Advantagene, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Gene Therapy Medicine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gene Therapy Medicine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gene Therapy Medicine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Gene Therapy Medicine market.

Gene Therapy Medicine Segment by Company

Vical Inc.

Spark Therapeutics

Sangamo

Dimension Therapeutics

Celladon

Bluebird Bio

Avalanche Bio

Advantagene

Gene Therapy Medicine Segment by Type

Oral

Injection

Gene Therapy Medicine Segment by Application

Cancer

Infectious Disease

Monogenic

Cardiovascular Disease

Other

Gene Therapy Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Gene Therapy Medicine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Gene Therapy Medicine key companies, revenue, market share, and recent developments.

3. To split the Gene Therapy Medicine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Gene Therapy Medicine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gene Therapy Medicine significant trends, drivers, influence factors in global and regions.

6. To analyze Gene Therapy Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapy Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gene Therapy Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapy Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gene Therapy Medicine industry.

Chapter 3: Detailed analysis of Gene Therapy Medicine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Gene Therapy Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Gene Therapy Medicine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gene Therapy Medicine Industry Trends Table 2. Gene Therapy Medicine Industry Drivers Table 3. Gene Therapy Medicine Industry Opportunities and Challenges Table 4. Gene Therapy Medicine Industry Restraints Table 5. Global Gene Therapy Medicine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gene Therapy Medicine Revenue Share by Company (2021-2026) Table 7. Global Gene Therapy Medicine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Gene Therapy Medicine Key Company Manufacturing Base & Headquarters Table 9. Global Gene Therapy Medicine Company, Product Type & Application Table 10. Global Gene Therapy Medicine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Gene Therapy Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oral Table 15. Significant Companies of Injection Table 16. Global Gene Therapy Medicine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Gene Therapy Medicine Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Gene Therapy Medicine Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Gene Therapy Medicine Sales Value Share by Type (2021-2026) Table 20. Global Gene Therapy Medicine Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Cancer Table 22. Significant Companies of Infectious Disease Table 23. Significant Companies of Monogenic Table 24. Significant Companies of Cardiovascular Disease Table 25. Significant Companies of Other Table 26. Global Gene Therapy Medicine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Gene Therapy Medicine Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Gene Therapy Medicine Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Gene Therapy Medicine Sales Value Share by Application (2021-2026) Table 30. Global Gene Therapy Medicine Sales Value Share by Application (2027-2032) Table 31. Global Gene Therapy Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Gene Therapy Medicine Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Gene Therapy Medicine Sales Value Share by Region (2021-2026) Table 34. Global Gene Therapy Medicine Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Gene Therapy Medicine Sales Value Share by Region (2027-2032) Table 36. Global Gene Therapy Medicine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Gene Therapy Medicine Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Gene Therapy Medicine Sales Value Market Share by Country (2021-2026) Table 39. Global Gene Therapy Medicine Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Gene Therapy Medicine Sales Value Market Share by Country (2027-2032) Table 41. Vical Inc. Company Information Table 42. Vical Inc. Business Overview Table 43. Vical Inc. Gene Therapy Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Vical Inc. Gene Therapy Medicine Product Portfolio Table 45. Vical Inc. Recent Development Table 46. Spark Therapeutics Company Information Table 47. Spark Therapeutics Business Overview Table 48. Spark Therapeutics Gene Therapy Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Spark Therapeutics Gene Therapy Medicine Product Portfolio Table 50. Spark Therapeutics Recent Development Table 51. Sangamo Company Information Table 52. Sangamo Business Overview Table 53. Sangamo Gene Therapy Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Sangamo Gene Therapy Medicine Product Portfolio Table 55. Sangamo Recent Development Table 56. Dimension Therapeutics Company Information Table 57. Dimension Therapeutics Business Overview Table 58. Dimension Therapeutics Gene Therapy Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Dimension Therapeutics Gene Therapy Medicine Product Portfolio Table 60. Dimension Therapeutics Recent Development Table 61. Celladon Company Information Table 62. Celladon Business Overview Table 63. Celladon Gene Therapy Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Celladon Gene Therapy Medicine Product Portfolio Table 65. Celladon Recent Development Table 66. Bluebird Bio Company Information Table 67. Bluebird Bio Business Overview Table 68. Bluebird Bio Gene Therapy Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Bluebird Bio Gene Therapy Medicine Product Portfolio Table 70. Bluebird Bio Recent Development Table 71. Avalanche Bio Company Information Table 72. Avalanche Bio Business Overview Table 73. Avalanche Bio Gene Therapy Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Avalanche Bio Gene Therapy Medicine Product Portfolio Table 75. Avalanche Bio Recent Development Table 76. Advantagene Company Information Table 77. Advantagene Business Overview Table 78. Advantagene Gene Therapy Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Advantagene Gene Therapy Medicine Product Portfolio Table 80. Advantagene Recent Development Table 81. Research Programs/Design for This Report Table 82. Authors List of This Report Table 83. Secondary Sources Table 84. Primary Sources List of Figures Figure 1. Gene Therapy Medicine Product Image Figure 2. Global Gene Therapy Medicine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gene Therapy Medicine Market Size (2021-2032) & (US$ Million) Figure 4. Global Gene Therapy Medicine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oral Image Figure 8. Injection Image Figure 9. Global Gene Therapy Medicine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Gene Therapy Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Gene Therapy Medicine Sales Value Share by Type (2021-2032) Figure 12. Cancer Image Figure 13. Infectious Disease Image Figure 14. Monogenic Image Figure 15. Cardiovascular Disease Image Figure 16. Other Image Figure 17. Global Gene Therapy Medicine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Gene Therapy Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Gene Therapy Medicine Sales Value Share by Application (2021-2032) Figure 20. Global Gene Therapy Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Gene Therapy Medicine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Gene Therapy Medicine Sales Value (2021-2032) & (US$ Million) Figure 23. North America Gene Therapy Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Gene Therapy Medicine Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Gene Therapy Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Gene Therapy Medicine Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Gene Therapy Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Gene Therapy Medicine Sales Value (2021-2032) & (US$ Million) Figure 29. South America Gene Therapy Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Gene Therapy Medicine Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Gene Therapy Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Gene Therapy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Cancer
  • Infectious Disease
  • Monogenic
  • Cardiovascular Disease
  • Other
Companies covered
  • Vical Inc.
  • Spark Therapeutics
  • Sangamo
  • Dimension Therapeutics
  • Celladon
  • Bluebird Bio
  • Avalanche Bio
  • Advantagene

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Gene Therapy Medicine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Gene Therapy Medicine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Gene Therapy Medicine Market Dynamics
  1. 2.1 Gene Therapy Medicine Industry Trends
  2. 2.2 Gene Therapy Medicine Industry Drivers
  3. 2.3 Gene Therapy Medicine Industry Opportunities and Challenges
  4. 2.4 Gene Therapy Medicine Industry Restraints
3 Gene Therapy Medicine Market by Company
  1. 3.1 Global Gene Therapy Medicine Company Revenue Ranking in 2025
  2. 3.2 Global Gene Therapy Medicine Revenue by Company (2021-2026)
  3. 3.3 Global Gene Therapy Medicine Company Ranking (2024-2026)
  4. 3.4 Global Gene Therapy Medicine Company Manufacturing Base and Headquarters
  5. 3.5 Global Gene Therapy Medicine Company Product Type and Application
  6. 3.6 Global Gene Therapy Medicine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Gene Therapy Medicine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Gene Therapy Medicine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Gene Therapy Medicine Market by Type
  1. 4.1 Gene Therapy Medicine Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.2 Global Gene Therapy Medicine Sales Value by Type
  5. 4.2.1 Global Gene Therapy Medicine Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Gene Therapy Medicine Sales Value by Type (2021-2032)
  7. 4.2.3 Global Gene Therapy Medicine Sales Value Share by Type (2021-2032)
5 Gene Therapy Medicine Market by Application
  1. 5.1 Gene Therapy Medicine Application Introduction
  2. 5.1.1 Cancer
  3. 5.1.2 Infectious Disease
  4. 5.1.3 Monogenic
  5. 5.1.4 Cardiovascular Disease
  6. 5.1.5 Other
  7. 5.2 Global Gene Therapy Medicine Sales Value by Application
  8. 5.2.1 Global Gene Therapy Medicine Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Gene Therapy Medicine Sales Value by Application (2021-2032)
  10. 5.2.3 Global Gene Therapy Medicine Sales Value Share by Application (2021-2032)
6 Gene Therapy Medicine Regional Value Analysis
  1. 6.1 Global Gene Therapy Medicine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gene Therapy Medicine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Gene Therapy Medicine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Gene Therapy Medicine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Gene Therapy Medicine Sales Value (2021-2032)
  7. 6.3.2 North America Gene Therapy Medicine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Gene Therapy Medicine Sales Value (2021-2032)
  10. 6.4.2 Europe Gene Therapy Medicine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Gene Therapy Medicine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Gene Therapy Medicine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Gene Therapy Medicine Sales Value (2021-2032)
  16. 6.6.2 South America Gene Therapy Medicine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Gene Therapy Medicine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Gene Therapy Medicine Sales Value Share by Country, 2025 VS 2032
7 Gene Therapy Medicine Country-level Value Analysis
  1. 7.1 Global Gene Therapy Medicine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gene Therapy Medicine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Gene Therapy Medicine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Gene Therapy Medicine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Gene Therapy Medicine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Gene Therapy Medicine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Gene Therapy Medicine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Vical Inc.
  2. 8.1.1 Vical Inc. Company Information
  3. 8.1.2 Vical Inc. Business Overview
  4. 8.1.3 Vical Inc. Gene Therapy Medicine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Vical Inc. Gene Therapy Medicine Product Portfolio
  6. 8.1.5 Vical Inc. Recent Developments
  7. 8.2 Spark Therapeutics
  8. 8.2.1 Spark Therapeutics Company Information
  9. 8.2.2 Spark Therapeutics Business Overview
  10. 8.2.3 Spark Therapeutics Gene Therapy Medicine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Spark Therapeutics Gene Therapy Medicine Product Portfolio
  12. 8.2.5 Spark Therapeutics Recent Developments
  13. 8.3 Sangamo
  14. 8.3.1 Sangamo Company Information
  15. 8.3.2 Sangamo Business Overview
  16. 8.3.3 Sangamo Gene Therapy Medicine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sangamo Gene Therapy Medicine Product Portfolio
  18. 8.3.5 Sangamo Recent Developments
  19. 8.4 Dimension Therapeutics
  20. 8.4.1 Dimension Therapeutics Company Information
  21. 8.4.2 Dimension Therapeutics Business Overview
  22. 8.4.3 Dimension Therapeutics Gene Therapy Medicine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Dimension Therapeutics Gene Therapy Medicine Product Portfolio
  24. 8.4.5 Dimension Therapeutics Recent Developments
  25. 8.5 Celladon
  26. 8.5.1 Celladon Company Information
  27. 8.5.2 Celladon Business Overview
  28. 8.5.3 Celladon Gene Therapy Medicine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Celladon Gene Therapy Medicine Product Portfolio
  30. 8.5.5 Celladon Recent Developments
  31. 8.6 Bluebird Bio
  32. 8.6.1 Bluebird Bio Company Information
  33. 8.6.2 Bluebird Bio Business Overview
  34. 8.6.3 Bluebird Bio Gene Therapy Medicine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bluebird Bio Gene Therapy Medicine Product Portfolio
  36. 8.6.5 Bluebird Bio Recent Developments
  37. 8.7 Avalanche Bio
  38. 8.7.1 Avalanche Bio Company Information
  39. 8.7.2 Avalanche Bio Business Overview
  40. 8.7.3 Avalanche Bio Gene Therapy Medicine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Avalanche Bio Gene Therapy Medicine Product Portfolio
  42. 8.7.5 Avalanche Bio Recent Developments
  43. 8.8 Advantagene
  44. 8.8.1 Advantagene Company Information
  45. 8.8.2 Advantagene Business Overview
  46. 8.8.3 Advantagene Gene Therapy Medicine Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Advantagene Gene Therapy Medicine Product Portfolio
  48. 8.8.5 Advantagene Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst